Skip navigation

Dynamic Dialogue, Timely Updates and Unparalleled Insights for Strategic and Operational Excellence

May 20-22, 2019
  • Orlando, FL
Critical, Breaking News Impacting Manufacturers in the Government and Drug Pricing Industry: HHS Set to Implement Long Delayed 340B Final Rule in January
CMS Finalizes Site Neutral Payment Rule

In light of recent CMS rule changes and President Trump’s America First Blueprint, MDRP and GP execs are asking many questions about the future of Medicaid and evolving government pricing and reporting requirements. Effectively navigating the political and regulatory landscape while effectively managing the increasing demands of government price reporting is critical to overall success.

CBI’s 21st Annual Medicaid and Government Pricing Congress is built off of the changing dynamics within the pharmaceutical landscape and arms attendees with action-oriented discussions and actionable takeaways on a full range of content including state pricing transparency, Medicare reform, value-based frameworks, 340B, supplemental rebates, reasonable assumptions and much more.

Previous Attendee Acclaim:

CBI’s Medicaid and Government Pricing Congress is a
great networking and learning experience that
serves the beginner through expert.

VP, Pricing and Contract Solutions, Fresenius Medical Care North America

Excellent content and subject matter experts along with
great networking and benchmarking opportunities.

Executive Director, Contract Operations and Government Pricing, Sandoz

Up to the minute updates, informative and great speakers. Conference is great for beginners to experts. I can always
take something from this conference and enjoy
the networking opportunities.

Director, Commercial Operations, Helsinn Therapeutics (U.S.), Inc.

CBI’s Medicaid Congress gave me renewed energy to go back and work on tightening up our GP methods, WI, SOPs and decision trees. Great ideas, great collaboration.

Associate Director, Vertex Pharmaceuticals

21st Annual Medicaid and Government Pricing Congress

Dynamic Dialogue, Timely Updates and Unparalleled Insights for Strategic and Operational Excellence

Critical, Breaking News Impacting Manufacturers in the Government and Drug Pricing Industry: HHS Set to Implement Long Delayed 340B Final Rule in January
CMS Finalizes Site Neutral Payment Rule

In light of recent CMS rule changes and President Trump’s America First Blueprint, MDRP and GP execs are asking many questions about the future of Medicaid and evolving government pricing and reporting requirements. Effectively navigating the political and regulatory landscape while effectively managing the increasing demands of government price reporting is critical to overall success.

CBI’s 21st Annual Medicaid and Government Pricing Congress is built off of the changing dynamics within the pharmaceutical landscape and arms attendees with action-oriented discussions and actionable takeaways on a full range of content including state pricing transparency, Medicare reform, value-based frameworks, 340B, supplemental rebates, reasonable assumptions and much more.

Previous Attendee Acclaim:

CBI’s Medicaid and Government Pricing Congress is a
great networking and learning experience that
serves the beginner through expert.

VP, Pricing and Contract Solutions, Fresenius Medical Care North America

Excellent content and subject matter experts along with
great networking and benchmarking opportunities.

Executive Director, Contract Operations and Government Pricing, Sandoz

Up to the minute updates, informative and great speakers. Conference is great for beginners to experts. I can always
take something from this conference and enjoy
the networking opportunities.

Director, Commercial Operations, Helsinn Therapeutics (U.S.), Inc.

CBI’s Medicaid Congress gave me renewed energy to go back and work on tightening up our GP methods, WI, SOPs and decision trees. Great ideas, great collaboration.

Associate Director, Vertex Pharmaceuticals